MLV & Co

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on MannKind Corporation (NASDAQ: MNKD) from Buy to Hold, but raised the price target from $10.00 to $11.00. In the report, MLV & Co noted, “Capping a long journey, FDA has now approved Afrezza, MNKD's...

In a report published Friday, MLV & Co analyst George B. Zavoico upgraded the rating on Geron (NASDAQ: GERN) from Hold to Buy, and raised the price target from $2.00 to $4.25. In the report, MLV & Co noted, “Earlier today, Geron Corp. announced that a partial clinical hold on an...

In a report published Friday, MLV & Co analyst Ryan Meliker initiated coverage on Preferred Apartment Communities (NYSE: APTS) with a Buy rating and $13.00 price target. In the report, MLV & Co noted, “We are initiating on Preferred Apartment Communities, Inc. with a BUY-rating and a $13...

In a report published Wednesday, MLV & Co analyst Jonathan Petersen downgraded the rating on Digital Realty Trust (NYSE: DLR) from Buy to Hold, but raised the price target from $59.00 to $60.00. In the report, MLV & Co noted, “Given two years of disappointing results, guidance reductions,...

In a report published Monday, MLV & Co analyst Ryan Meliker reiterated a Buy rating and $11.00 price target on Summit Hotel Properties (NYSE: INN). In the report, MLV & Co noted, “INN reported a mixed quarter as RevPAR exceeded the high-end of guidance, while FFO was at the high-end and in...

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), but lowered the price target from $27.00 to $21.00. In the report, MLV & Co noted, “KERX reported 1Q results last week, but the main focus was mgmt's...

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh initiated coverage on pSivida Corp. (NASDAQ: PSDV) with a Buy rating and $6.00 price target. In the report, MLV & Co noted, “We're attending ARVO (the annual mtg for retinal specialists), and live from Orlando, we initiate...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh upgraded the rating on XOMA (NASDAQ: XOMA) from Hold to Buy, and reiterated the $7.00 price target. In the report, MLV & Co noted, “We now upgrade shares of XOMA. Our call is based on 1) valuation and 2) optimism around...

In a report published Tuesday, MLV & Co analyst Paul Morgan initiated coverage on AmREIT (NYSE: AMRE) with a Buy rating and $21.00 price target. In the report, MLV & Co noted, “AmREIT's ‘Irreplaceable Corner' shopping center investment strategy targets high-traffic, infill assets located...

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics (NASDAQ: GALT). In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support the safety and positive effects of GR-MD-02 on...

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on Prana Biotechnology Limited (NASDAQ: PRAN) from Buy to Hold, and lowered the price target from $11.00 to $3.00. In the report, MLV & Co noted, “In yet another setback to the Alzheimer's disease (...

In a report published Tuesday, MLV & Co analyst Jonathan Petersen initiated coverage on Washington Real Estate Investment Trust (NYSE: WRE) with a Buy rating and $29.00 price target. In the report, MLV & Co noted, “The ongoing shift from suburban to CBD among office properties will be...

In a report published Tuesday, MLV & Co analyst Jonathan Petersen initiated coverage on Highwoods Properties (NYSE: HIW) with a Hold rating and $38.00 price target. In the report, MLV & Co noted, “HIW trades at an implied cap rate of 6.9%, which we view as a small premium to fair valuation...

In a report published Tuesday, MLV & Co analyst Jonathan Petersen initiated coverage on Government Properties Income Trust (NYSE: GOV) with a Hold rating and $24.00 price target. In the report, MLV & Co noted, “We view GOV as a good fit for dividend-seeking investors, as the 6.9% dividend...

In a report published Tuesday, MLV & Co analyst Jonathan Petersen initiated coverage on First Potomac Realty Trust (NYSE: FPO) with a Buy rating and $16.00 price target. In the report, MLV & Co noted, “We expect FPO to continue to report positive net absorption in 2014 as the D.C. market...